--- title: Decentralized Clinical Trials with Equity in Mind | Acclinate description: Discover how decentralized clinical trials can expand access—if designed with equity, cultural relevance, and digital inclusion from the ground up. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Decentralized-Clinical-Trials--Expanding-Access-with-Equity-in-Mind-.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # Decentralized Clinical Trials: Expanding Access with Equity in Mind Discover how decentralized clinical trials can expand access—if designed with equity, cultural relevance, and digital inclusion from the ground up. ![Decentralized Clinical Trials: Expanding Access with Equity in Mind](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Decentralized-Clinical-Trials--Expanding-Access-with-Equity-in-Mind-.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/decentralized-clinical-trials-with-equity-in-mind) [**](https://twitter.com/home?status=https://blog.acclinate.com/decentralized-clinical-trials-with-equity-in-mind) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/decentralized-clinical-trials-with-equity-in-mind&title=Decentralized%20Clinical%20Trials%20with%20Equity%20in%20Mind%20|%20Acclinate) Stay up to date Get news directly in your inbox **Key Takeaways and Learnings**  - Decentralized clinical trials offer flexibility, but must be designed with intentional equity strategies to avoid widening disparities. - Common barriers—like lack of broadband access, insufficient digital fluency, and mistrust—can be addressed through culturally relevant outreach and hybrid participation. - Acclinate’s approach blends human connection with predictive tools like e-DICT™ and platforms like NOWINCLUDED to support representation in clinical research. - Engagement doesn’t start with recruitment. [Discover best practices for forming real community connections with our comprehensive guide](https://info.acclinate.com/ebook-ultimate-guide-to-advancing-health-equity-in-clinical-trials).   Decentralized clinical trials (DCTs) are reshaping clinical research by offering flexibility, convenience, and the promise of broader participation. By leveraging digital tools and remote technologies, DCTs reduce the need for in-person visits and allow participants to engage from the comfort of their homes.  But as we embrace these innovations, one critical question remains: *who* is being left behind?  Without a thoughtful approach to equity, decentralized clinical trials risk amplifying the very disparities they aim to dismantle. Let's explore how DCTs can be designed to improve access for historically underrepresented populations, and how sponsors, CROs, and research institutions can embed equity at every step. [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKk4BJAFoYZlAt5bJKCzct2VZyaSz9XQxDCWKohcZFsV1BgwKcltePX0c7u8bHze5UfxfMwUlkJouzzwxTJTspfBNeSdq412Z%2BucEQoAmBC2l2dGOk7gXxp%2F5RgyBp5DBhPCNSZF%2FekmTPqoB8TeUld9QFvlk%2FQpEKhQM%2Bc%2BifmefUuOYnbx99dK%2BHDU9cKgvNNsI541rKkli5gxoVPK0YvBJRaIsgwi6fyrBmgZK1kGwdjlQemHzqN%2Fuc683guPw%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## What Are Decentralized Clinical Trials—and Why Do They Matter? Decentralized clinical trials use virtual tools—like telemedicine, mobile apps, wearables, and home health visits—to reduce geographic and logistical barriers to research participation. They hold incredible potential for expanding access, improving participant retention, and accelerating timelines. According to [MetaStat Insight](https://www.metastatinsight.com/report/decentralized-clinical-trials-dct-market), the global DCT market is expected to grow significantly, driven by increasing demand for patient-centric approaches and real-time data collection.  Yet, while these benefits are real, they’re not evenly distributed. Many individuals in communities of color, rural areas, and underserved regions face significant hurdles that may prevent them from engaging with digital-first research opportunities. These barriers include:  - Limited broadband access - Low digital literacy - Language and cultural disconnects - Historical mistrust in the healthcare system  If DCTs are to fulfill their promise, they must account for these challenges upfront and from the very start.  ## **Building Trust Beyond Technology**  At Acclinate, we believe representation in clinical research begins with trust. That can’t be built through platforms alone. It’s established through connections between real people. That’s why we take a touch-first approach, using technology like our e-DICT™ predictive analytics platform to support, not replace, community-based engagement.  Our work starts with listening. Through our health equity community, NOWINCLUDED, we provide culturally relevant information and foster two-way dialogue. This foundation allows us to guide sponsors and CROs in patient recruitment strategies in clinical trials that resonate across cultural, geographic, and generational lines.  For example, [one recent study of a DCT](https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0000905) for low back pain demonstrated that when participants had access to remote monitoring and regular support, retention improved—even among traditionally underrepresented groups. But it wasn’t just the tech that made it work—it was the combination of personalized contact, clear communication, and community relevance.  ## **Designing DCTs with Equity in Mind**  To design decentralized clinical trials that are truly inclusive, stakeholders must do more than digitize the traditional model. They must:  ### **1. Address the Digital Divide**  Some low-income and rural households lack consistent internet access or digital devices. Offering mobile-compatible tools, offline participation options, and support hotlines can reduce friction and improve accessibility. Acclinate works with partners to assess community readiness and provide guidance tailored to each population’s realities.  ### **2. Invest in Digital Literacy** Even when tools are available, they must be usable. Sponsors should budget for onboarding, multilingual tutorials, and ongoing tech support—delivered through trusted local partners or care providers.  ### **3. Partner with Trusted Community Organizations**  Cultural barriers can’t be overcome through email alone. Acclinate helps research teams connect with communities by activating trusted messengers and existing networks in underrepresented areas. These connections are often the key to initial engagement—and lasting participation.  ### **4. Make Data Work for People, Not Just Protocols**  Using platforms like e-DICT™, Acclinate helps sponsors and CROs identify not just who might qualify for a study, but how to reach them in a way that aligns with their values and lived experiences. Predictive insights ensure the right message reaches the right person at the right time. **See Acclinate in action. [Explore our case studies](https://www.acclinate.com/case-studies).** ## **An Equity-Centered Example: Community-Driven Planning**  In a [national 12-month IBD initiative](https://www.acclinate.com/improving-inflammatory-bowel-disease-outcomes-case-study), Acclinate deployed its NOWINCLUDED™ community-engagement platform alongside culturally tailored strategies to better support underrepresented individuals living with Crohn’s disease and ulcerative colitis. The effort reached over 1.5 million individuals through education and awareness campaigns and engaged nearly 48,000 community members. Importantly, more than 11,000 individuals were offered the opportunity to participate in IBD research, and over 200 completed pre-screener assessments—demonstrating both reach and activation of historically underrepresented populations.  Combining community‑centered education, advocacy‑partner collaboration, and digital outreach, this pilot highlights how intentional, data-driven strategies can significantly enhance access and engagement in decentralized or hybrid clinical research models.  ## **Moving from Possibility to Practice**  The shift to decentralized clinical trials is not inherently inclusive, but it can be.  Sponsors and CROs have an opportunity, and a responsibility, to reimagine the clinical research experience through an equity lens. By embedding culturally relevant outreach, enabling hybrid participation options, and activating trusted voices, organizations can ensure decentralized doesn’t mean disconnected.  At Acclinate, we’re proud to be the bridge between research institutions and the communities they aim to serve. From strategic planning to participant activation, we bring human-first strategies powered by predictive technology to ensure representation is more than an objective—it’s an outcome.  Ready to see how Acclinate can help your organization advance its health equity goals? [Schedule a 1:1 meeting with our team today.](https://cta-redirect.hubspot.com/cta/redirect/19943632/31583cc4-4449-4d4b-8cb9-94b6615b6eee) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2025-07-25T13:59:27.617Z", "datePublished" : "2025-07-25T13:59:10.000Z", "headline" : "Decentralized Clinical Trials with Equity in Mind | Acclinate", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Decentralized-Clinical-Trials--Expanding-Access-with-Equity-in-Mind-.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/decentralized-clinical-trials-with-equity-in-mind", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```